These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20150632)

  • 1. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
    Luu T; Chow W; Lim D; Koczywas M; Frankel P; Cristea M; Margolin K; Doroshow JH; Somlo G; Gaur S; Yen Y; Morgan RJ
    Anticancer Res; 2010 Jan; 30(1):167-74. PubMed ID: 20150632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
    Bommakanti SV; Dudek AZ; Khatri A; Kirstein MN; Gada PD
    Am J Clin Oncol; 2011 Dec; 34(6):597-602. PubMed ID: 21127410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
    Falchook GS; Duvic M; Hong DS; Wheler J; Naing A; Lim J; Kurzrock R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1117-26. PubMed ID: 22205203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
    Kouroukis CT; Fernandez LA; Crump M; Gascoyne RD; Chua NS; Buckstein R; Turner R; Assouline S; Klasa RJ; Walsh W; Powers J; Eisenhauer E
    Leuk Lymphoma; 2011 Mar; 52(3):394-9. PubMed ID: 21323520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
    Turkington RC; Purcell C; James CR; Millar J; Napier E; Law D; Gallagher R; Morris M; Wilson RH; Eatock MM
    Invest New Drugs; 2014 Apr; 32(2):250-60. PubMed ID: 23665866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
    Lieu C; Chow L; Pierson AS; Eckhardt SG; O'Bryant CL; Morrow M; Tran ZV; Wright JJ; Gore L
    Invest New Drugs; 2009 Feb; 27(1):53-62. PubMed ID: 18618082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
    Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
    Schenk E; Hendrickson AE; Northfelt D; Toft DO; Ames MM; Menefee M; Satele D; Qin R; Erlichman C
    Invest New Drugs; 2013 Oct; 31(5):1251-6. PubMed ID: 23543109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
    Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.